Mode
Text Size
Log in / Sign up
Phase 3 N=166 Treatment

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder

Enrolled (actual)
166
Serious AEs
26.5%
Results posted
Dec 2024
Primary outcome: Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 162; 44 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
satralizumab (Drug); azathioprine (AZA) (Drug); mycophenolate mofetil (MMF) (Drug); oral corticosteroids (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Hoffmann-La Roche
Primary completion
May 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
162; 44
PRIMARY
Number of Participants With Adverse Events of Special Interest (AESIs) and Selected AEs
0; 0
SECONDARY
Number of Participants With Suicidality Assessed Using Columbia-Suicide Severity Rating Scale (C-SSRS)
7; 5; 5; 2; 1; 0
SECONDARY
Number of Participants With Serious Infections and Hepatotoxicity
19; 8
SECONDARY
Time to First Protocol-defined Relapse (PDR) as Assessed by Investigator (iPDR)
NA
SECONDARY
iPDR-free Rate up to Week 456
67.11
SECONDARY
Percentage of Relapse-Free Participants
70.5
SECONDARY
Annualized Relapse Rate (ARR)
0.0788
SECONDARY
Change in Expanded Disability Status Scale (EDSS) Score
3.80; -0.08; -0.16; -0.14; -0.18; -0.14
SECONDARY
Time to First EDSS Scores Worsening
NA
SECONDARY
Event-free Rate for EDSS Score Worsening up to Week 456
57.03
SECONDARY
Percentage of Participants Without EDSS Worsening
64.8
SECONDARY
Change in Visual Acuity (VA) Assessed by a Snellen 20-Foot Wall Chart
0.438; 0.566; 0.028; 0.009; 0.014; 0.020
SECONDARY
Concentrations of Interleukin-6 (IL-6) in Blood
2.07; 21.27; 21.90; 19.35; 18.84; 17.53
SECONDARY
Concentrations of Soluble IL-6 Receptor (sIL-6R) in Blood
32.27; 404.20; 536.46; 566.91; 568.96; 561.69
SECONDARY
Concentration of C-Reactive Protein (CRP) in Blood
1.27; 0.38; 0.36; 0.39; 0.42; 0.42
SECONDARY
Serum Concentration of Satralizumab at Specified Timepoints
103.75; 7489.76; 14631.06; 20068.86; 17495.09; 12673.14
SECONDARY
Number of Participants With Anti-Drug Antibodies (ADAs) From the First Dose of Satralizumab in Studies NCT02028884 or NCT02073279
3; 161; 99; 67

Summary

This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of studies BN40898 and BN40900. Participants will receive satralizumab as monotherapy or in combination with one of the following background immunosuppressive treatments: azathioprine (AZA), mycophenolate mofetil (MMF), or oral corticosteroids.

Eligibility Criteria

Inclusion Criteria

  • Participants aged less than 18 years at the time of informed consent for Study BN40898 can continue treatment with a combination of oral corticosteroids and either AZA or MMF
  • Participated in Study BN40898 or Study BN40900 with satralizumab in NMOSD, are on ongoing satralizumab treatment and were anti-aquaporin-4 IgG antibody (AQP4-IgG) seropositive at screening in these studies. Participants with NMOSD who were AQP4-IgG seronegative at screening in Study BN40898 or Study BN40900 can be enrolled if the investigator considers the continued treatment with satralizumab to be beneficial for the participant
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for 3 months after the final dose of satralizumab.

Exclusion Criteria

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of study drug. Women of childbearing potential must have a negative urine pregnancy test result on the baseline visit prior to initiation of study drug
  • Evidence of any serious uncontrolled concomitant diseases that may preclude participation including nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency
  • Known active infection that requires delaying the next satralizumab dose at the time of enrollment
  • NMOSD relapse at the time of enrollment
  • Laboratory abnormalities at the last assessment in Study BN40898 or Study BN40900 that preclude re-treatment with satralizumab
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04660539). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search